IBTK, inhibitor of Bruton tyrosine kinase, 25998

N. diseases: 33; N. variants: 0
Disease: Mantle cell lymphoma ×
Source: BEFREE ×
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C4721414
Disease: Mantle cell lymphoma
Mantle cell lymphoma 		0.030 Biomarker disease BEFREE Ibrutinib is an oral covalent inhibitor of Bruton's tyrosine kinase approved for the treatment of patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma and Waldenstrӧm's macroglobulinemia. 30785921 2019
CUI: C4721414
Disease: Mantle cell lymphoma
Mantle cell lymphoma 		0.030 Biomarker disease BEFREE Ibrutinib is an oral inhibitor of Bruton tyrosine kinase, which is one of the key drugs used for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma. 30421802 2019
CUI: C4721414
Disease: Mantle cell lymphoma
Mantle cell lymphoma 		0.030 Biomarker disease BEFREE This first-in-class inhibitor of Bruton's tyrosine kinase has become a standard treatment for patients with CLL and MCL. 30061088 2018